Lee McCracken

CEO

Lee is Chief Executive Officer and a member of the Board of Directors of Drawbridge Health.

Prior to joining Drawbridge Health in 2017, Lee served as CEO of Gensignia Life Sciences, CEO of Pathwork Diagnostics, and Corporate Head of Business Development for Prometheus Laboratories (Nestlé Health Science). Earlier in his career, he held executive positions at several biotechnology and pharmaceutical companies including GenStar Therapeutics, CombiChem, and Allergan, and the venture capital firms, 3i Capital and Union Venture.

Lee received his MBA from the Anderson School of Management at UCLA, his MS in Computer Science from the University of Dayton, and his BS in Commerce from Santa Clara University. He currently serves as a director of several public and private companies.

Paul Jacobson

Director

Paul is the Chief Executive Officer of Thorne Research, responsible for defining the strategic direction for Thorne’s various business segments, with primary emphasis on innovative business development. He has extensive experience in investment banking, finance, and fundraising.

Prior to his current role at Thorne, Paul was the Chief Executive Officer of Diversified Natural Products (DNP) and served as a director of Progenics Pharmaceuticals. He was a partner and co-head of the Liquid Capital Markets department of Goldman, Sachs & Co.

Paul received his MBA from Washington University in St. Louis, Missouri and his BA degree from Vanderbilt University.

Risa Stack, PhD

Chair & Director

Most recently, Risa led the New Business Creation team at GE Ventures which started companies in healthcare, energy, and software. The team has launched Evidation Health, Vineti, Menlo Microsystems, Drawbridge Health, Avitas, and AiROXS.

Risa joined the GE Ventures team from Kleiner Perkins Caufield & Byers where she was a partner for 10 years. While at Kleiner Perkins Caufield & Byers, Risa incubated several companies and was the founding CEO of two. Risa has invested in and held board director or observer roles in over a dozen healthcare companies including: Corthera (acquired by Novartis), Epizyme (NASDAQ: EPZM), Foundation Medicine (NASDAQ:FMI), Ilex Oncology (acquired by Genzyme), Orexigen (NASDAQ:OREX), Pacific Biosciences (NASDAQ:PACB), Triangle Pharmaceuticals (acquired by Gilead), Trius (acquired by Cubist), and Veracyte (NASDAQ:VCYT).

Risa holds a degree in genetics and development with distinction from the University of Illinois, a PhD in immunology from the University of Chicago, and was a member of the second class of Kauffman Fellows.

Alex De Winter, PhD

Director

Alex is a Managing Director with GE Ventures, where he focuses on precision medicine. He has led investments in Labcyte, RainDance Technologies, Syapse, and Veracyte.

Alex joined GE from Mohr Davidow Ventures, where he specialized in healthcare and life sciences startups. At Mohr Davidow, he worked with portfolio companies CardioDx, Corventis, Crescendo Bioscience, DVS Sciences, and Personalis.

Previously, Alex was a Senior Scientist at Pacific Biosciences, working on systems integration for its Single Molecule Real Time DNA sequencer. He started his career as a scientist at 454 Life Sciences, where he worked on what became the first of the next-generation DNA sequencers.

Alex has a PhD in Chemistry from Stanford University, an MBA from UC Berkeley, and degrees in English and Chemistry from Amherst College.

Kamraan Shariff

Head of Corporate Development

Kamraan joined Drawbridge in 2019 as Head of Corporate Development, bringing his expertise in strategy, acquisitions and joint ventures and global capital raising.

Prior to joining Drawbridge, Kamraan was a Managing Director at GE Ventures, one of the founding shareholders of Drawbridge. He has also held senior positions within the M&A division of both GE & GE Capital across Europe and Asia. Kamraan started his career in Investment Banking, and over time assumed leadership positions across both product and coverage functions in Europe, Australia and Asia.

Kamraan received his MS in International Banking & Financial Services from the University of Reading and a BS in Economics (Industrial Studies) from the University of Leeds.

Catherine Mazzacco

Director

Catherine is Senior Vice President of Global Commercial Operations, Life Sciences-Bioprocesses, at GE Healthcare, a $4.5 billion+ molecular medicine business that provides industry-leading technologies and services for drug discovery, clinical development and biopharmaceutical manufacturing, as well as molecular tools for therapy selection and treatment monitoring in patient care.

Previously, Catherine was Vice President of Global Commercial Operations for Abbott’s Vision Care Division. During her fifteen years at Abbott she also held leadership positions in their Canada & EMEA Commercial Operations for Abbott Diabetes Care, Abbott Proprietary Pharmaceuticals, and Hospital Products Division.

Catherine holds a BSE, Engineering, Option Biology from Université de Technologie de Compiegnè, France.

Lee McCracken

Director

Lee is Chief Executive Officer and a member of the Board of Directors of Drawbridge Health.

Prior to joining Drawbridge Health in 2017, Lee served as CEO of Gensignia Life Sciences, CEO of Pathwork Diagnostics, and Corporate Head of Business Development for Prometheus Laboratories (Nestlé Health Science). Earlier in his career, he held executive positions at several biotechnology and pharmaceutical companies including GenStar Therapeutics, CombiChem, and Allergan, and the venture capital firms, 3i Capital and Union Venture.

Lee received his MBA from the Anderson School of Management at UCLA, his MS in Computer Science from the University of Dayton, and his BS in Commerce from Santa Clara University. He currently serves as a director of several public and private companies.

Paul Jacobson

Director

Paul is the Chief Executive Officer of Thorne Research, responsible for defining the strategic direction for Thorne’s various business segments, with primary emphasis on innovative business development. He has extensive experience in investment banking, finance, and fundraising.

Prior to his current role at Thorne, Paul was the Chief Executive Officer of Diversified Natural Products (DNP) and served as a director of Progenics Pharmaceuticals. He was a partner and co-head of the Liquid Capital Markets department of Goldman, Sachs & Co.

Paul received his MBA from Washington University in St. Louis, Missouri and his BA degree from Vanderbilt University.

Alex De Winter, PhD

Director

Alex is a Managing Director with GE Ventures, where he focuses on precision medicine. He has led investments in Labcyte, RainDance Technologies, Syapse, and Veracyte.

Alex joined GE from Mohr Davidow Ventures, where he specialized in healthcare and life sciences startups. At Mohr Davidow, he worked with portfolio companies CardioDx, Corventis, Crescendo Bioscience, DVS Sciences, and Personalis.

Previously, Alex was a Senior Scientist at Pacific Biosciences, working on systems integration for its Single Molecule Real Time DNA sequencer. He started his career as a scientist at 454 Life Sciences, where he worked on what became the first of the next-generation DNA sequencers.

Alex has a PhD in Chemistry from Stanford University, an MBA from UC Berkeley, and degrees in English and Chemistry from Amherst College.

Elisa Romeo, PhD

Chief Operations Officer

Elisa joined Drawbridge Health in 2017, bringing her expertise and a wealth of experience in diagnostic test development for CLIA-certified, CAP-accredited commercial laboratories and medical device companies focused on in vitro diagnostic (IVD) test development.

Prior to joining Drawbridge Health, Elisa served as VP of Research and Development at Gensignia Life Sciences, IVD Development Manager at Pathway Genomics, Associate Director of Operations at HistoRx and Principal Scientist at Genoptix.

Elisa completed a post-doctoral fellowship at the Scripps Research Institute in La Jolla, CA and received her PhD in Biochemistry and Human Physiology from the University Zurich in Switzerland. She received her MS in Molecular Biology from the University of Insubria, Italy.

Greg Nagy

Chief Marketing Officer

Greg joined Drawbridge Health in 2016 and brings a wealth of global commercial experience in the life science and medical device industries.

Prior to Drawbridge Health, Greg served as VP of Global Marketing at Topcon Eyecare (based in Tokyo, Japan) and held leadership positions at several biotechnology and medical device companies including Solta Medical (Valeant Pharmaceuticals), Amgen, Vertex Pharmaceuticals and Aurora Biosciences.

Greg received his MBA from the Graziadio School of Business and Management at Pepperdine University and his BS in Bioengineering from University of California, San Diego.

Holly Logue

Head of Strategic Assets

Holly joined Drawbridge Health in 2019 and brings nearly 20 years of legal experience in the life science, diagnostic and medical device industries.

Prior to joining Drawbridge Health, Holly developed intellectual property portfolios and served as commercial and IP counsel to several companies, including BioTheranostics, Trovagene, Gensignia, GenSpera and Aktana. Holly also developed a wealth of experience across several areas of law, including commercial transactions, litigation and regulatory compliance, as an attorney at Arnold & Porter, LLP and as Professional Staff at the U.S. House of Representatives.

Holly received her BS in Biochemistry and her JD from the University of Michigan, and is currently obtaining her MBA from Wharton at the University of Pennsylvania.

Lee McCracken

CEO

Lee is Chief Executive Officer and a member of the Board of Directors of Drawbridge Health.

Prior to joining Drawbridge Health in 2017, Lee served as CEO of Gensignia Life Sciences, CEO of Pathwork Diagnostics, and Corporate Head of Business Development for Prometheus Laboratories (Nestlé Health Science). Earlier in his career, he held executive positions at several biotechnology and pharmaceutical companies including GenStar Therapeutics, CombiChem, and Allergan, and the venture capital firms, 3i Capital and Union Venture.

Lee received his MBA from the Anderson School of Management at UCLA, his MS in Computer Science from the University of Dayton, and his BS in Commerce from Santa Clara University. He currently serves as a director of several public and private companies.

Most recently, Risa led the New Business Creation team at GE Ventures which started companies in healthcare, energy, and software. The team has launched Evidation Health, Vineti, Menlo Microsystems, Drawbridge Health, Avitas, and AiROXS.

Risa joined the GE Ventures team from Kleiner Perkins Caufield & Byers where she was a partner for 10 years. While at Kleiner Perkins Caufield & Byers, Risa incubated several companies and was the founding CEO of two. Risa has invested in and held board director or observer roles in over a dozen healthcare companies including: Corthera (acquired by Novartis), Epizyme (NASDAQ: EPZM), Foundation Medicine (NASDAQ:FMI), Ilex Oncology (acquired by Genzyme), Orexigen (NASDAQ:OREX), Pacific Biosciences (NASDAQ:PACB), Triangle Pharmaceuticals (acquired by Gilead), Trius (acquired by Cubist), and Veracyte (NASDAQ:VCYT).

Risa holds a degree in genetics and development with distinction from the University of Illinois, a PhD in immunology from the University of Chicago, and was a member of the second class of Kauffman Fellows.